Pharvaris NV PHVS.OQ PHVS.O is expected to show no change in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Pharvaris NV is for a loss of 77 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pharvaris NV is $30.00, about 32.3% above its last closing price of $20.32
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.79 | -0.76 | -0.85 | Missed | -11.4 |
Dec. 31 2025 | -0.72 | -0.64 | Beat | 11.2 | |
Sep. 30 2024 | -0.62 | -0.61 | -0.77 | Missed | -26.1 |
Jun. 30 2024 | -0.55 | -0.55 | -0.55 | Met | 0.5 |
Mar. 31 2024 | -0.56 | -0.56 | -0.52 | Beat | 7.7 |
Dec. 31 2023 | -0.37 | -0.53 | -0.76 | Missed | -42.5 |
Sep. 30 2023 | -0.59 | -0.60 | -0.58 | Beat | 3.4 |
Jun. 30 2023 | -0.59 | -0.65 | -0.63 | Beat | 3.1 |
This summary was machine generated August 8 at 20:46 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)